Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 8/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20465152 | 0.89 | RPS6KB1 (0.55) | RORCIDH1RPS6KB1 | |
| SCHEMBL18477020 | 0.85 | RORC (0.62) | L3MBTL1HCAR3RORCIDH1HSD17B10 | |
| SCHEMBL20465151 | 0.82 | RORC (0.58) | L3MBTL1RORCIDH1RPS6KB1 | |
| SCHEMBL18477024 | 0.76 | RORC (0.64) | RORCIDH1RPS6KB1 | |
| SCHEMBL18477022 | 0.75 | RORC (0.60) | L3MBTL1RORCIDH1RPS6KB1ACACB | |
| SCHEMBL20465158 | 0.74 | RORC (0.63) | RORC | |
| SCHEMBL5516298 | 0.72 | IDH1 (0.53) | L3MBTL1IDH1 | |
| SCHEMBL9613233 | 0.72 | L3MBTL1 (1.00) | L3MBTL1HCAR3HSD17B10GAA | |
| SCHEMBL2687048 | 0.70 | L3MBTL1 (0.77) | L3MBTL1HCAR3HSD17B10GAA | |
| SCHEMBL14382627 | 0.69 | L3MBTL1 (0.73) | L3MBTL1HCAR3HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | L3MBTL1 4609/4885HCAR3 1455/4885RORC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.